factor α (TNFα). In these conditions, a soluble form of B7-H6 (sB7-H6) was also produced by activated monocytes and neutrophils. In vivo, B7-H6 was expressed on circulating proinflammatory CD14 + CD16 + monocytes in a group of patients in sepsis conditions, and was linked to an increased mortality. sB7-H6 was selectively detected in the sera of patients with Gram -sepsis and was associated with membrane vesicles that co-sedimented with the exosomal fraction.
Introduction
Natural Killer (NK) cells are cytolytic and cytokine-producing lymphocytes that can recognize a variety of cells in distress. 1 Cells undergoing microbial infection, tumor transformation as well as chemical or physical insults become NK cell targets when they express stress-induced surface molecules that interact with activating NK cell surface receptors. The recognition of NKG2D ligands expressed by target cells via NKG2D expressed on NK cells represents a prototypical illustration of this stress-induced self mode of innate immune recognition. 2 NK cells express at their surface a group of activating receptors that are Ig-like superfamily members and are referred as to Natural Cytotoxicity Receptors (NCRs). NCRs include NKp46 (NCR1, CD335), NKp44 (NCR2, CD336) and NKp30 (NCR3, CD337). 3 Although these molecules have no homology, they have been grouped as NCRs based on the similarities in their expression profile, their oligomeric structure and their function. 4 The characterization of the NCR ligands is still incomplete. While many data support a central role of NCR in tumor surveillance, [5] [6] [7] [8] the first NCR ligands to be identified were viral structures, in particular the influenza haemaglutinin for NKp46 9 and the human cytomegalovirus pp65 tegument protein for NKp30. 10 Later the HLA-B associated transcript 3 (BAT3) protein was shown to bind and trigger NKp30. 11 This nuclear protein now referred as to BAG6
(http://www.genenames.org/data/hgnc_data.php?hgnc_id=13919) is ectopically found at the plasma membrane upon stress but absent from tumor cells susceptible to NK cell lysis. We identified B7-H6 (NCR3LG1, http://www.genenames.org/data/hgnc_data.php?hgnc_id=42400)
as a ligand of NKp30. 12 ,13 B7-H6 transcripts have not been detected in normal adult tissues.
However B7-H6 is present on a broad panel of hematopoietic and non-hematopoietic tumor cells including lymphoma, leukemia, melanoma, and carcinoma as well as on primary tumor blood cells. 12 The pattern of B7-H6 expression, which appears so far to be limited to tumor cells, is thus another example of stress-induced self recognition by NK cells. In the case of NKG2D ligands, several mechanisms have been shown to regulate their expression. For example, genotoxic stress
For personal use only. on May 29, 2017 . by guest www.bloodjournal.org From 4 was shown to up-regulate NKG2D ligands on cell lines, whereas interfering with the DNA damage pathway in tumor cells inhibited their constitutive expression. 2 In contrast to NKG2D
ligands, the regulation of B7-H6 expression is unknown. We studied here the mechanisms that govern the induction of B7-H6 on primary cells as well as its consequences in vitro and in vivo.
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Methods
A detailed description of all experimental methods can be found in the supplemental Methods on the Blood website.
Cells and reagents
PBMCs were isolated from healthy volunteer donors using Ficoll-Paque Plus (GE Healtcare) density centrifugation. Human monocytes were purified with CD14 microbeads (Miltenyi) according to the manufacturer's instructions. Cell purity was 90-98%. Human neutrophils were isolated from peripheral blood of healthy donors using a dextran-Ficoll method. Human NK cells were purified with a human NK cell isolation II Kit (Miltenyi) according to the manufacturer's instructions. Cells were cultured in complete RPMI 1640 medium (GIBCO) supplemented with 100 U/mL penicillin/streptomycin (GIBCO), 1 mM sodium pyruvate (GIBCO), 10% heatinactivated FBS (LONZA). Human PBMCs (3 x 10 6 cells), neutrophils (2 x 10 6 cells) or monocytes (5 x 10 5 cells) were seeded into 24-well plates (BD). Cells were then incubated at 37°C with 5% CO 2 in the presence or absence of the following stimuli: 300 ng/ml synthetic bacterial lipoprotein (Pam3CSK4), 10 µg/ml zymosan, 10 8 cells/ml heat-killed A. laidlawii (HKAL), L. monocytogenes (HKLM), H. pylori (HKHP) or S. aureus (HKSA), 500 ng/ml synthetic diacylated lipoprotein (FSL-1), 1 µg/ml ultra-pure lipopolysaccharide (LPS) from E.
coli, 1 µg/ml flagellin from S. typhimurium, 20 µg/ml imiquimod (R837), 5 µg/ml ssRNA40, 20 µg/ml ODNs CpG type A, 100 µg/ml poly(I:C), 100 ng/ml TNFα or 1 ng/ml IL-1β. All reagents were purchased from Invivogen except for IL-1β that was purchased from PeproTech. The study trial (clincaltrials.gov NTC00699868) was approved by the Sud-Méditerranée V Ethics Committee (Comité de Protection des Personnes). Written informed consent was obtained from all patients or their proxies in accordance with the Declaration of Helsinki.
Results

In vitro induction of B7-H6 transcripts in primary blood cells
We set up an in vitro screening test to investigate whether B7-H6 could be induced on primary blood cells. In this assay, peripheral blood mononuclear cells (PBMCs) were treated with a variety of agents and mRNA was extracted to quantify B7-H6 transcripts using quantitative RT-PCR. In contrast to reports showing that DNA-damaging agents (such as irradiation, cisplatine, etoposide or fluorouracile) and proteasome inhibitors (such as epoxomicin or MG132) can induce the expression of NKG2D ligands, 2 these treatments had no substantial effect on B7-H6 expression in our protocols (data not shown Figure 1A ). In contrast, the stimulation of PBMCs via endosomal TLRs, such as TLR7 (R837), TLR9 (CpGs) and TLR3 (Poly IC) had very limited impact on B7-H6 mRNA expression. A noticeable exception was the stimulation of primary cells by ssRNA that triggers a TLR8-dependent pathway and induced B7-H6 transcripts ( Figure 1A ). As a control, all TLR stimulation induced IL-6 transcripts (Supplemental Figure S1) . Noteworthy, the pro-inflammatory cytokines TNFα and IL-1β also induced B7-H6 transcripts ( Figure 1B-C) . Overall, the kinetics of B7-H6 mRNA induction upon TLR and cytokine secretion were quite similar, peaking early between 3 and 12 hours, and returning fast to baseline within 24 hours post-stimulation. Thus, B7-H6 is one of the early genes that are induced in primary blood human cells upon inflammatory and microbial stimulations in vitro.
In vitro induction of cell surface B7-H6
To further investigate the regulation of B7-H6 expression, we generated a panel of mouse monoclonal antibodies (mAbs) directed against human B7-H6. Four mAbs were selected on the basis of their selective reactivity with P815.B7-H6, but not with P815.B7-H1 stable transfectants ( Figure 2A ). As expected, they also reacted with human tumor cell lines constitutively expressing B7-H6 such as HeLa cells (Figure 2A In humans, TLR2 is expressed by monocytes and neutrophils, TLR3 is expressed by BDCA3 + conventional dendritic cells (cDC), TLR5 is expressed by monocytes, neutrophils and cDCs, TLR7 is expressed by monocytes and plasmacytoid DCs (pDCs), TLR8 is expressed by neutrophils and TLR9 by pDCs. 15 The pattern of TLR expression was thus consistent with the selectivity of B7-H6 induction on monocytes, but also prompted us to examine whether neutrophils could express surface B7-H6 upon stimulation. Whereas unstimulated neutrophils do not express cell surface B7-H6, treatment of neutrophils with TNFα, LPS, IL-1β ( Figure 4D ), HKSA and HKHP (Supplemental Figure S4 ) leads to a weak but reproducible induction of cell surface B7-H6. As for monocytes, the effect of IL-1β was direct as it occurred on purified neutrophils. Anti-B7-H6 F(ab)' 2 fragments were used to ascertain the specificity of anti-B7-H6
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In vitro induction of soluble B7-H6
The availability of a panel of anti-B7-H6 mAbs allowed us to identify that two of them recognize non-overlapping B7-H6 epitopes rendering it possible to set-up a sandwich ELISA against B7-H6
(Supplemental Figure S5 ). We then investigated whether soluble forms of B7-H6 could be produced in vitro. Purified monocytes were activated for 48 hours with LPS or IL-1β and soluble B7-H6 (sB7-H6) was measured in cell supernatants by ELISA. No sB7-H6 was detected in the supernatant of monocytes in absence of stimulation. In contrast, sB7-H6 could be detected in the supernatant of LPS-and IL-1β-stimulated monocytes isolated from a group of healthy individuals (4/9) ( Figure 5A ). Similarly, neutrophils prepared from another group of healthy individuals and stimulated with LPS or IL-1β also produced sB7-H6 (4/6) ( Figure 5B ). HKHP was able to induce sB7-H6 from monocytes or neutrophils in vitro in some individuals, although stimulated monocytes and neutrophils from all healthy individuals expressed B7-H6 at the surface (Supplemental Figure S4) . The mechanisms underlying the heterogeneity between cells from healthy individuals that produce or not detectable amounts of sB7-H6 in vitro is still unclear.
Irrespective of this issue that needs further investigation, these results reveal that a soluble form of B7-H6 can be produced by neutrophils and monocytes in response to inflammatory and microbial stimuli.
In vivo expression of B7-H6 during sepsis
The in vitro induction of B7-H6 by TLR ligands and pro-inflammatory cytokines prompted us to analyze the expression pattern of B7-H6 in inflammatory and infectious conditions in vivo. To address this point, PBMCs were obtained from a collection of peripheral blood samples prepared from a cohort of 39 patients presenting a systemic inflammatory response syndrome (SIRS) and admitted at the medical intensive care unit (ICU) (Supplemental Table 1 ). Cells were harvested at Figure 6A and Supplemental Table 1 ). Remarkably, the cell surface expression of B7-H6 was restricted to patients presenting sepsis ( infections. In contrast, serum sB7-H6 was detected in 37% of sepsis patients, and restricted to patients with Gram -infection ( Figure 6E and Supplemental Table 2 ). Consistent with these results, Gram -bacteria (e.g. HKHP) are much more prone than Gram + bacteria (e.g. HKSA) to induce sB7-H6 in vitro (Supplemental Figure S4 ). Most Gram -sepsis patients who had detectable levels of serum sB7-H6 at day 1 also had circulating B7-H6 + CD14 + CD16 + pro-inflammatory monocytes on the same day (Supplemental Table 1 ).
1
Despite the small size of our cohort of patients, we analyzed the potential association of B7-H6 expression and the clinical outcome of ICU patients. The overall day 30 mortality in ICU patients was 23.1%. We observed a higher mortality in sepsis patients with membrane B7-H6
(mB7-H6 + ) expression as compared to patients lacking mB7-H6 + cells (mB7-H6 -) ( Figure 6F ). In particular, no death was observed when mB7-H6 expression was negative in patients with Gram -sepsis, as compared to 44% death in patients expressing mB7-H6.
Analysis of sB7-H6
We took advantage of the substantial quantities of sB7-H6 present in patient sera to document the nature of sB7-H6. In a first series of experiments, patient sera were subjected to three rounds of centrifugations. The pellets obtained at each round were analyzed by ELISA for the presence of sB7-H6. sB7-H6 was associated with the material that sedimented at 110,000 g, suggesting that sB7-H6 was included in membrane vesicles that were present in the serum, such as exosomes ( Figure 7A ). To further dissect this point, sB7-H6 + patient sera were analyzed for the presence of B7-H6 + membrane vesicles using sequential low-speed centrifugations and high-speed centrifugations followed by a 0.22 μM filtration as described previously. 16 After incubation of the filtered pellets with latex beads, we detected that sB7-H6 + patient sera contained filtered pellet material that was reactive with CD63, CD81 and B7-H6 mAbs ( Figure 7B ). CD63 and CD81 are classically considered as markers of exosomes, 16 suggesting that B7-H6 can be associated with these membrane vesicles in the serum of sepsis patients. Incubation of primary NK cells with the sB7-H6 + pellets that sedimented with the exosomal fraction impaired the staining of NK cells with anti-NKp30 mAbs, whereas sB7-H6 -pellets had no effect ( Figure 7C ). In addition, sB7-H6 + pellets also inhibited the NKp30-dependent activation of reporter cells induced by B7-H6 + K562
cells as efficiently as the blocking 17B1.3 anti-B7-H6 mAbs ( Figure 7D ). Interestingly, recombinant sB7-H6 had no effect on NKp30 cell surface expression and on NKp30-dependent cell activation over a large range of concentrations (data not shown Sepsis is a clinical syndrome that complicates severe infection, and is one of the leading causes of admission to ICU with mortality rates ranging from 30% to more than 50%. The hostresponse of these patients, include a first phase of SIRS, characterized by an exacerbated inflammatory response, rapidly followed by a profound alteration of immunity, referred as to compensatory anti-inflammatory response syndrome (CARS). This acquired immunoparalysis is thought to render the patients more susceptible to nosocomial infections, and to lead to increased morbidity and mortality. NK cells are a major source of interferon (IFN)-γ, a potent inflammatory cytokine, and early depletion of NK cells improved survival in sepsis models in the mouse.
36,37
We also recently observed that both NK cell cytotoxicity and IFN-γ production were decreased in sepsis, 38 consistent with similar results obtained in mice. 39 Considering the sequence of opposite events that are at work during sepsis, NK cells might have a dual role in sepsis, first contributing to the amplification of the inflammatory response during the early steps of SIRS and then, impaired during CARS and thus participating to its detrimental consequences. 38, 40, 41 Our data on B7-H6 expression during inflammation provide a novel perspective on the link between microbial infection and NK cell activation. First, B7-H6 was selectively induced on confirms the general propensity of the members of the family to be induced in inflammatory conditions. sB7-H6 present in the serum of sepsis patients impaired the binding of anti-NKp30 mAbs to NKp30 and NKp30-dependent cell activation. Importantly, recombinant sB7-H6 was unable to impact on NKp30 expression and signaling. Thus, sB7-H6 present in patient serum is different from recombinant sB7-H6. These data support the fact that serum sB7-H6 was found in exosomal fractions and thus could be exposed as multimers with higher avidity that monomeric recombinant sB7-H6. It is however remarkable and still puzzling that serum sB7-H6 was restricted to patients with Gram -infection, while no difference was observed between sepsis patients presenting Gram -or Gram + infections for mB7-H6 expression. A possible explanation could be that blood monocytes recognize Gram -bacteria through TLR2 and TLR4 while Gram and is common to TLR2 and TLR4, whereas the other depends on Toll-IL-1 receptor (TIR) domain-containing adaptor inducing interferon-β (TRIF) restricted to TLR4. 52 Consequently the induction of mB7-H6 could be dependent of MyD88, while the induction of sB7-H6 could be dependent of TRIF. This issue needs further investigation.
During an immune response to infection, the outcome of NK cell-myeloid cell interactions through NKp30/B7-H6 interaction could be two-fold according to the membrane bound or soluble form of B7-H6. In one hand, 65% of patients with sepsis had circulating proinflammatory type monocytes expressing mB7-H6, when these cells could not be detected in other SIRS patients or healthy individuals. This suggests that NK cell activation induced by B7-H6 + monocytes could occur in these patients via NKp30 interaction. The highest mortality of 1 6 patients with membrane bound B7-H6 would suggest a negative role for NK cells in sepsis, consistent with data in the mouse. 36, 37 In the other hand, we also show that sB7-H6 which block mB7-H6/NKp30 functional interaction, was detected in the serum of sepsis patients. We observed a trend associating sB7-H6 with higher patient mortality (data not shown). Thus, NK cell inhibition via sB7-H6 production would also be detrimental for the patient outcome. Based on these data, we thus propose a model as which the activation of NK cells via mB7-H6
contributes to inflammation during SIRS, but then sB7-H6 might play a negative role during CARS. This possibility would explain how two opposing phenomena, (i.e the expression of mB7-H6 that activates NK cells and the production of sB7-H6 that impairs NK cell activation), could have both deleterious impact on patient survival during sepsis. Our data thus prompt to perform the immunomonitoring of cell surface B7-H6 and sB7-H6 in a large of cohort of sepsis patients over the kinetics of their clinical outcome to test whether mB7-H6 and/or sB7-H6 can help in stratifying individuals at risk of developing bad outcomes.
For provided expression data and critical comments on the report.
Conflict of interest statement
E.V. is a cofounder and shareholder of Innate-Pharma. arbitrary units.
